Rovi stock: Rovi confirms Roche manufacturing alliance for a new medicine

Published on 10/24/2026 at 05:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half revenue rose 13 percent to EUR 357 million in 2026. For Rovi stock, the next results date is November 5, 2026.

Company events and financial dates

Rovi confirmed a Roche manufacturing alliance on October 22, 2026.
Total revenue rose 13 percent to EUR 357 million in the first half of 2026.
Rovi will release nine-month 2026 results on November 5, 2026.

Rovi, ES0157261019, Illustration mit AI erstellt.

Rovi (ISIN ES0157261019) was quoted at EUR 60.15 on BME on October 23, 2026, giving the company a market value of EUR 3.1 billion. Bolsamania reported on October 22, 2026 that Rovi had confirmed an alliance with Roche to manufacture a new medicine.

Roche deal adds industrial context

The Roche agreement matters because Rovi is expanding its contract manufacturing platform while integrating the Phoenix facility acquired on April 1, 2026. Management said the acquisition generated a EUR 62.4 million bargain purchase gain in the first half of 2026, a non-recurring item that lifted reported profitability.

The first-half figures show the operating base behind the deal. According to the Yahoo Finance transcript dated July 23, 2026, total revenue rose 13 percent to EUR 357.0 million in the first half of 2026. Operating revenue increased 9 percent to EUR 344.2 million, while contract manufacturing revenue grew 38 percent to EUR 106.3 million.

What does the growth mean for margins?

The mix is important for investors because the CDMO business is expanding faster than the group. Gross profit increased 21 percent to EUR 237.1 million in the first half of 2026, and gross margin reached 68.9 percent, up 6.5 percentage points. Reported EBITDA was EUR 121.2 million, but EBITDA excluding the EUR 62.4 million badwill fell 10 percent to EUR 58.8 million.

Three dated steps for Rovi

On April 1, 2026, Rovi completed the Phoenix facility acquisition and recognized the EUR 62.4 million bargain purchase gain. On July 23, 2026, first-half revenue reached EUR 357.0 million, up 13 percent year over year. On October 22, 2026, Rovi confirmed the Roche manufacturing alliance, while its BME quote stood at EUR 60.15 on October 23, 2026.

Next reporting dates

MarketScreener lists November 5, 2026 for Rovi's nine-month 2026 results. Barron's also lists February 24, 2027 for the fiscal-year 2026 report.

Market value and business scale

Rovi's reported first-half growth is paired with a BME price of EUR 60.15 on October 23, 2026. The same market context places the 52-week range at EUR 53.10 to EUR 86.70, while the company employs 2,470 people and operates across specialty pharmaceuticals and contract manufacturing.